Cytovale's Diagnostic Test Demonstrates Strong Performance in Rapid Identification of Sepsis Risk, Peer-Review Study Confirms
SAN FRANCISCO, May 2, 2024 /PRNewswire/ -- Cytovale®, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced the publication of a new peer reviewed-study in "Academic Emergency Medicine'' that demonstrates strong diagnostic performance of the company's IntelliSep® host response test for sepsis detection. The study analyzed 1,002 patients and evaluated the accuracy of IntelliSep to rapidly diagnose patients with sepsis and help clinicians expedite appropriate care.
- The study analyzed 1,002 patients and evaluated the accuracy of IntelliSep to rapidly diagnose patients with sepsis and help clinicians expedite appropriate care.
- The test provides critical new information about immune activation and sepsis risk stratification through a simple blood draw in about 8 minutes.
- IntelliSep was evaluated for accurately diagnosing sepsis and providing a rapid, objective tool for determining the risk and severity of sepsis in these patients.
- The test showed similar 'rule-in' performance to other critical ED tests, with a Positive Predictive Value of 55%.